Purpose: To comparatively evaluate the efficacy of a bandage contact lens (BCL) and autologous serum (AS) eye drops in the management of severe dry eye caused by Sjögren syndrome (SS).
S
jögren syndrome (SS) is a systemic autoimmune disease characterized by chronic inflammation that results in xerostomia and keratoconjunctivitis sicca in approximately 95% of patients. 1 Dry eye syndrome with SS (SSDE) is often more severe than non-SSDE. The lack of both basic and reflex tearing resulting from lacrimal gland destruction in patients with SSDE leads to severe ocular surface staining, which can lead to corneal damage and visual impairment with significant functional disability. [2] [3] [4] [5] Moreover, its impact on the quality of life of the patient can be significant. 6 Autologous serum (AS) eye drops have been used to treat severe dry eye disease, persistent epithelial defects, and other ocular surface diseases. 7 The beneficial effect of AS may be multifactorial. However, the main advantage of using serum over preservative-free artificial tears is the presence of growth factors that accelerate corneal epithelial proliferation. 8, 9 Promising outcomes have been reported with the use of AS eye drops for the treatment of severe dry eye including those of patients with primary SS. [10] [11] [12] [13] However, AS use has not been established in dry eye disease associated with SS. 14 Recently, with advances in contact lens design, silicone hydrogel material with higher oxygen diffusion capacities has emerged, allowing for longer uninterrupted wear, providing a new therapeutic adjunct in the treatment of dry eye disease. 15 It is possible that silicone hydrogel contact lenses may help to stabilize the tear film, allow for corneal healing, and restore normal cell turnover, all of which are critical to the treatment of dry eye disease. 16 A number of studies have used silicone hydrogel contact lenses for Fuchs dystrophy, toxic epitheliopathy, filamentous keratitis, corneal perforation, corneal stromal melting, recurrent corneal erosion, chemical or traumatic corneal epithelial defects, epithelial irregularity, persistent epithelial defects, lamellar laceration, graft insufficiency, pseudophakic bullous keratopathy, and dry eye secondary to graft-versus-host disease. [16] [17] [18] However, no study has evaluated the use of silicone hydrogel lenses in the management of severe dry eye disease caused by SS.
The objective of this prospective study was to evaluate the efficacy of balafilcon A silicone hydrogel contact lenses as bandage contact lenses (BCL) worn on a continuous basis in the management of refractory, severe dry eye signs and symptoms caused by SS. The efficacy of contact lenses was compared with AS eye drops.
METHODS

Study Population
Forty patients (77 eyes) with the diagnosis of primary SS, who sought treatment in our hospital between March 2013 and April 2014, were enrolled in this study. The research protocol was approved by the Wenzhou Medical College Review Board, Wenzhou, Zhejiang, China, and followed the tenets of the Declaration of Helsinki. Informed consent was obtained from the subjects.
Diagnosis
Patients were diagnosed with SS based on the classification criteria of the American-European Consensus Group of rheumatologists and ophthalmologists. 19 All patients with SSDE had persistent symptoms for at least 3 months and were refractory to conventional treatments, including artificial tear drops and topical antiinflammatory therapy. The included patients had (1) a Schirmer I test score ,5 mm without anesthesia, (2) tear film break-up time (tBUT) ,5 seconds, and (3) corneal fluorescein staining scores .5. We excluded patients with structural abnormalities (lid scarring, entropion, and trichiasis); 2 or more morphological changes in meibomian glands including vascular dilation, acinar atrophy, or orifice metaplasia on the posterior lid margin; ocular allergy; ocular inflammation, infection, or an active structural change in the cornea, conjunctiva, iris, or anterior chamber; glaucoma; previous eye surgery or punctal occlusion; and those who were pregnant or lactating.
Questionnaires
The Chinese version of the Ocular Surface Disease Index (OSDI; Allergan, Inc, Irvine, CA) questionnaire was used in this study. The subjects were asked questions regarding dry eye symptoms that they had experienced during a 1-week recall period. Subtotal scores related to vision-related function, ocular symptoms, and environmental triggers were calculated, and a total score was recorded. 20 Patients were asked to complete a subjective perception scale, the "faces" scale, on a daily basis. The results were collected at each visit. The faces scale is a single-item, 7-category rating scale in which the subject is asked to grade their level of comfort (or pain) to match the appearance to 1 of 7 faces, which vary in apparent effect (Fig. 1) . 21 The subjective scores were converted to Rasch estimates using the conversion values generated by Facets.
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The resulting response scale calibrations and person measures are expressed in log odd units (natural logarithm of an odds ratio), or logits, positioned along a hierarchical scale with logits of greater magnitude representing increasing pain.
Clinical Evaluations
Subjective refraction was performed to measure the best-corrected visual acuity (BCVA). Visual acuity was measured at each visit using the logarithm of the minimum angle of resolution charts. Corneal fluorescein staining was performed in a conventional manner. 22 The corneal surface was analyzed in 4 quadrants. Each quadrant was scored separately and all scores were added to obtain a final score for the eye. The corneal fluorescein staining grade was classified as follows: 0, no staining; 1, less than 5 dots; 2, between 1 and 3 dots; and 3, bulk or strip staining.
Slit-lamp biomicroscopy was performed to examine the anterior segment at each visit. The Schirmer I test (without anesthesia) was performed to measure reflex tear production. The tBUT was performed to assess tear film stability with 3 separate measurements recorded and averaged for each eye at each visit.
All the above examinations and questionnaires were performed and recorded at baseline and follow-up visits at week 3, week 6, and 6 weeks after the therapy was withdrawn.
Groups
After completion of baseline examinations, all patients were randomly divided into 2 groups, AS and BCL. In addition, all patients received treatment with 0.1% preservative-free sodium hyaluronate eye drops (4 times daily; Hycosan; Ursapharm Arzneimittel GmbH, Saarbrücken, Germany) and 0.02% fluorometholone eye drops (3 times daily; Santen Pharmaceutical Co, Ltd, Osaka, Japan) during the whole trial period. Patients in the BCL group were fitted with silicone hydrogel lenses made of balafilcon A (water content 36%; PureVision; Bausch & Lomb Inc, Rochester, NY). The lenses were replaced with a new lens after 3 weeks of continuous wear or if any signs of spoilage or problems with lens fit were noted. Patients were given instructions to discontinue lens wear at the first sign of eye redness, blurred vision, photophobia, irritation, or pain in the eye.
Patients in the AS group were provided with AS eye drops. From each subject's antecubital vein, 40 mL of peripheral blood was collected and was allowed to clot for 2 hours at room temperature. After centrifugation at 3000g for 15 minutes, the serum was carefully isolated under sterile conditions in a laminar flow hood. 12 The serum was diluted to a 50% concentration with balanced salt solution. Aliquots of diluted serum were stored in sterile 5-mL bottles with UV light protection. The patients were asked to use AS eye drops 8 times a day for 6 weeks. Instructions were given to refrigerate opened bottles and to store unopened AS drop bottles in a freezer.
Statistical Analysis
Descriptive statistics for continuous data were reported as mean 6 SD. The Kolmogorov-Smirnov test was used to test normality of data, and appropriate statistical tests were used subsequently. The categorical data comparisons were assessed using the x 2 test, including gender and education. The quantitative data were assessed using an unpaired t test, including age, BCVA, course of SS, and onset of symptoms. A 1-way analysis of variance was used to compare the OSDI and Rasch-adjusted faces scores between groups. The MannWhitney U test was used to compare tear film and ocular surface parameters between groups. P , 0.05 was considered statistically significant. All analyses were performed using SPSS Version17.0 (IBM Corp, Armonk, NY).
RESULTS
Demographics
A total of 40 patients were included at the baseline of the study. Patients were randomly assigned to the AS group and the BCL group. Three patients requested withdrawal from the study because of intolerance to the BCL (n = 1) or inconvenience in using the AS (n = 2). Three patients, 2 from the AS group and 1 from the BCL group, did not come for the last follow-up visit (week 12); these patients were included in the analysis. Overall, data from 71 eyes of 37 patients were analyzed. The average age of patients was 48.3 6 8.0 years (range, 28-62 years; 36 women). As shown in Table 1 , the baseline demographics and clinical features of patients with SSDE were matched in both groups.
Visual Acuity
There was no difference in the logarithm of the minimum angle of resolution BCVA between the AS and BCL groups at baseline and during follow-up visits (P . 0.05; Table 2 ). There was no significant improvement in BCVA after 3 to 6 weeks of treatment in the AS group. However, BCVA improved significantly in the BCL group after 3 weeks (vs. baseline, P = 0.06) and 6 weeks (vs. baseline, P = 0.003) of treatment. Moreover, BCVA remained stable up to 6 weeks after discontinuation of the BCL (vs. baseline, P = 0.03), during which the patients continued to receive artificial teardrops and fluorometholone eye drops (Table 2) .
OSDI and Faces Scores
The difference in the OSDI scores between both groups was not significant at baseline (P = 0.63). The scores decreased significantly after treatments (week 3 and 6 vs. baseline, P , 0.01; left in Fig. 2 ). There was a marked improvement in the OSDI scores 6 weeks after therapy was withdrawn in both groups (week 12 vs. baseline, P , 0.01; left in Fig. 2 ). As compared with the AS group, patients in the BCL group had lower OSDI scores at all corresponding time points after treatment (P = 0.014, ,0.001, ,0.004, respectively).
There was no significant difference in the faces scores between both groups at baseline (P = 0.62). The scores decreased significantly after interventions in both groups (weeks 3, 6, and 12 vs. baseline, P , 0.01; right in Fig. 2 ).
All patients felt more comfortable and reported improved quality of life after treatment with either an AS or BCL at the end of 3 weeks. At follow-up of 6 weeks, 8 of 18 patients (44.4%) in the AS group and 9 of 19 patients (47.4%) in the BCL group reported better scores on the faces scale compared with the scores at 3 weeks. Eight of 16 patients (50%) in the AS group and 14 of 18 patients (77.8%) in the BCL group reported no obvious deterioration at 6 weeks after discontinuation of the treatment (P = 0.091). As compared with the AS group, patients in the BCL group had lower faces scores at all corresponding points after treatment (P = 0.023, 0.003, 0.002, respectively).
Tear Film and Corneal Staining
Before treatment, there were no significant differences in the tBUT, Schirmer I test score, and corneal staining grades between both groups (P . 0.05; Table 2 ). The baseline Schirmer I test showed reduced tear production in all patients, and no statistically significant changes between or within groups (Table 2) , although there was a weak trend toward improvement after the treatments. The corneal staining score significantly decreased after interventions in both groups; the tBUT also significantly improved except at 6 weeks after discontinuation of AS use, which did not reach statistical significance. No significant differences in the tBUT were observed at all corresponding time points between both groups. Patients in the BCL group had lower corneal staining scores than those of the AS group after 6 weeks of treatment and at subsequent 6 weeks after discontinuation (P , 0.01), but there were no distinctions after 3 weeks of treatment between both groups (P = 0.82). Corneal fluorescein staining in the BCL group showed a notable reduction in the staining area during the follow-up. Figure 3 shows the comparison of therapeutic effects at the same time points between AS and BCL groups.
Complications
Among the subjects who completed the study, there were no subjective reports of irritation, discomfort, photophobia, blurred vision, or raised intraocular pressure during contact lens wear and AS application. In addition, no adverse events, such as infectious or inflammatory keratitis, corneal abrasions, redness, neovascularization, conjunctivitis, or any other event that precluded conduct of treatments, were observed.
DISCUSSION
AS eye drop application is considered to be a safe and efficient way to treat patients with SS-associated dry eye because the serum provides essential components to the ocular surface. 11, 12, 23 However, the preparation of the drops is quite labor intensive and associated with problems of contamination and the possible risk for disease transmission. For these reasons, AS use has not been established in dry eye disease associated with SS. 14 The efficacy of serum drop therapy varies because of variations in the study populations-that is, the degree of aqueous deficiency and variations in the production and treatment protocol for serum eye drops. There is no agreed standard dilution of serum eye drops for the treatment of dry eye diseases. Previous studies have reported the use of concentrations ranging from 20% to 100% for the treatment of dry eye. Tsubota et al 23 reported that symptoms, fluorescein, and Rose Bengal staining of dry eye in SS were significantly decreased after 4 weeks of 20% serum eye drops 6 to 10 times daily. Similar findings were described in patients with dry eye secondary to graft-versus-host disease. 24, 25 However, in a placebo-controlled prospective study in patients with severe dry eye, 20% serum eye drops 6 times daily were not able to improve discomfort or objective signs significantly better than the diluent 0.9% saline. 26 Other studies 11, 12, 27 used a high concentration of 50%, similar to that of our study.
It is well known that bandage silicone hydrogel contact lenses are effective for the treatment of persistent epithelial defects. 28 BCLs have been shown to decrease necrosis and desquamation of the corneal epithelium by prevention of blink-associated mechanical stress and subsequent acceleration of wound healing. 29 Silicone hydrogel lenses offer oxygen permeability and oxygen transmissibility 5-fold to 10-fold greater than those of conventional soft contact lenses. The high oxygen permeability allows extended wear with fewer hypoxia-related complications. 30 Brennan et al 31 have shown successful use of silicone hydrogel materials of choice for continuous-wear contact lenses. In this study, we used balafilcon A silicone hydrogel contact lenses (PureVision), which were replaced by new lenses after 3 weeks. There were no reports of irritation, discomfort, photophobia, blurred vision, or adverse events during contact lens wear.
Several studies have shown that silicone hydrogel lens wearers reported reduced dryness and discomfort compared with hydrogel contact lens patients. [32] [33] [34] Silicone hydrogel lens wearers also reported better comfort after napping or sleeping, and in dry air or smoky environments. This may be attributed to the fact that silicone hydrogel lens materials are less prone to evaporation and absorb fewer airborne pollutants compared with lenses with higher water content. 32, [35] [36] [37] Our results demonstrated an improvement in dry eye symptoms and quality of life in all patients with SS after an AS or BCL treatment. The results of the OSDI and the faces scores show significant improvement after treatment. These results were consistent with other studies, which indicated that dry eye symptoms improved and remained stable after fitting with silicone hydrogel contact lenses. 38, 39 It is noteworthy that 8 of 16 patients (50%) in the AS group and 14 of 18 patients (77.8%) in the BCL group reported no obvious deterioration 6 weeks after discontinuation of treatment (P = 0.091). The continuation of the therapeutic effect seemed better after BCL treatment. Moreover, compared with the AS group, patients in the BCL group had lower OSDIs and faces scores at all corresponding time points after treatment (P , 0.05).
Our results showed that there was no statistically significant change in the Schirmer I test scores between or within groups, although there was a weak trend toward improvement after the treatments. tBUT also significantly improved in both groups except at 6 weeks after discontinuing AS use. Patients in the BCL group had lower corneal staining scores than those of the AS group after 6 weeks of treatment and at subsequent 6 weeks after discontinuation (P , 0.01). In addition to improvement in the subjective assessment of dry eye symptoms, the BCL use also showed significant improvement in visual acuity. Although there was no significant improvement in the BCVA after 3 to 6 weeks of treatment with the AS, the BCVA improved significantly in the BCL group at 3 weeks (vs. baseline, P = 0.06) and 6 weeks (vs. baseline, P = 0.003) after treatment. Moreover, the BCVA remained stable after 6 weeks of discontinuation of BCL use (vs. baseline, P = 0.03). The effect on visual acuity could be secondary to smoothening of ocular surface irregularities by the BCL or by improvement in subjective dry eye symptoms. 16 Patients with severe dry eye due to SS usually require frequent instillation of artificial tears to reduce the ocular discomfort. The results of this study suggest that adjunct treatment with AS eye drops and BCLs could notably relieve ocular discomfort and improve the quality of life in patients with dry eye secondary to SS. However, compared with the AS, silicone hydrogel bandage contact lenses have a better and longlasting impact on dry eye signs and symptoms.
